We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assay Approved for Dengue Diagnosis

By LabMedica International staff writers
Posted on 16 Jul 2012
A molecular diagnostic test has been developed and officially approved to detect the dengue virus in people with symptoms of dengue or dengue hemorrhagic fever.

The DENV-1-4 Real Time Polymerase Chain Reaction (RT-PCR) Assay was developed by the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) for use in the USA and can be conducted by using equipment and supplies that are already performed in many public health laboratories to diagnose influenza. More...


With the RT-PCR test, laboratories are now able to diagnose all four dengue virus types within the first seven days after the appearance of any dengue-related symptoms. This coincides with the time the majority of people generally take in order to visit a health care professional whilst the dengue virus may already be present in their blood. The test is the first molecular dengue test approved by the US Food and Drug Administration (FDA, Silver Springs, MD, USA), which detects the actual virus in comparison with other available FDA-approved tests, which just detect immunoglobin M (IgM) a certain type of antibody to the dengue virus.

Although the majority of patients start developing antibodies within four days after falling ill, the antibodies are not present in everyone until seven days after they have become infected dengue, which means that health care professionals cannot always recognize early enough that a person has become infected with dengue. Each year, thousands of US visitors develop dengue fever, which manifests itself through high fever, severe headaches or pain behind the eyes, aching joints, muscles, and bones, rash and mild bleeding of the nose or gums, as well as easy bruising. In severe cases, dengue can lead to hemorrhage, shock, and even death.

Jorge L. Munoz-Jordan, PhD, chief of the Molecular Diagnostics and Research at the CDC Dengue Branch, said "The need for the new dengue diagnostic test was high. Patients will be diagnosed sooner than before, and public health laboratories will have a clearer picture of the true number of dengue cases. Dengue is now a reportable disease in the United States, and the availability of state-of-the-art dengue diagnostics will improve patient management and the public health response to dengue." The DENV-1-4 RT-PCR Test kits will be available for distribution to clinical and public health laboratories in the USA and abroad from July 2, 2012.

Related Links:

US Centers for Disease Control and Prevention
US Food and Drug Administration



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.